CEO of CDMO AustinPx on its exclusive agreement with Thermo Fisher’s Patheon division

PartnershipPositive

AI Analysis

Summary

Thermo Fisher's Patheon division signed an exclusive agreement with AustinPx to install its KinetiSol bioavailability enhancement technology at Patheon facilities in Bend, Oregon and Cincinnati, integrating with Patheon's AI/ML-powered Quadrant 2 formulation platform.

Outcome Details

Exclusive agreement to install KinetiSol technology at Patheon facilities in Bend, Oregon and Cincinnati

Importance:6/10

Sentiment:

0.60

partnershipCDMOexclusive agreementtechnology licensingformulationKinetiSol

Related Companies

$TMO

Read the original article

Published by Drug Discovery & Development on July 10, 2026 3:47 PM

Read Original